All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.
CAS Number | 1874157-95-5 |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[1] Sohita Dhillon. Drugs. Tebentafusp: First Approval
[2] Timo E Schank, et al. Future Oncol. Tebentafusp for the treatment of metastatic uveal melanoma
Related IL Receptor/Related Products |
---|
IL-15-IN-1
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. |
IL-17 modulator 3
IL-17 modulator 3 is an IL-17 modulator. |
IL-17 modulator 4
IL-17 modulator 4 is a proagent of IL-17 modulator 1. |
IL-17A modulator-3
IL-17A modulator-3 is a IL-17A modulator. |
IL-17 modulator 4 sulfate
IL-17 modulator 4 sulfate is a proagent of IL-17 modulator 1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.